We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Sev­er­al bio­phar­ma com­pa­nies have been work­ing on ex­pand­ing drug la­bels through the use of re­al world end­points, comb­ing through the da­ta to find ev­i­dence of a drug’s ef­fi­ca­cy for par­tic­u­lar in­di­ca­tions. But we’ve just be­gun. Re­al World Ev­i­dence is be­com­ing an im­por­tant part of every clin­i­cal de­vel­op­ment plan, in the soup-through-nuts ap­proach used in build­ing fran­chis­es.

I’ve re­cruit­ed a pan­el of 3 top ex­perts in the field — the first in a se­ries of pre­mi­um we­bi­na­rs — to look at the prac­ti­cal re­al­i­ties gov­ern­ing what can be done to­day, and where this is head­ed over the next few years, at the prod­ding of the FDA.

ZHEN SU — Mer­ck Serono’s Se­nior Vice Pres­i­dent and Glob­al Head of On­col­o­gy

EL­LIOTT LEVY — Am­gen’s Se­nior Vice Pres­i­dent of Glob­al De­vel­op­ment

CHRIS BOSHOFF — Pfiz­er On­col­o­gy’s Chief De­vel­op­ment Of­fi­cer

A pre­mi­um sub­scrip­tion to End­points News is re­quired to at­tend this we­bi­nar. Please up­grade to ei­ther an In­sid­er or En­ter­prise plan for ac­cess. Al­ready have End­points Pre­mi­um? Please sign-in be­low. You can con­tact our Sub­scrip­tions team at help@end­pointsnews.com with any is­sues.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER